Researchers evaluated AzaSite Plus and DexaSite, and found they did not completely resolve all symptoms. However, they did bring statistically significant improvements in symptoms at day 15. The study reaffirmed that blepharitis is chronic and persistent and may need a different clinical approach than finding a traditional cure.
InSite Vision’s study is the largest, most quantitative clinical examination of blepharitis ever conducted. Currently, no pharmaceuticals are approved to help the more than 34 million Americans with the condition, which is characterized by chronic inflammation of the eyelid.
More Articles on Ophthalmology:
Case Western Reserve University Names Dr. Douglas Rhee Chair of Ophthalmology and Visual Sciences
Laurel Laser & Surgery Center in Pennsylvania Celebrates 10k Cataract Removals
Researchers Successfully Treat Blindness in Mice With Stem Cell Therapy
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.